Trip.com Group Ltd (TCOM) Stock Price Today
Aura AI Summary
Key Stats
- $25.65BMARKET_CAP
- -VOLUME
- Consumer CyclicalSECTOR
- $78.96FIFTY_TWO_WEEK_HIGH
- $39.84FIFTY_TWO_WEEK_LOW
- -TYPICAL_HOLD_TIME
- $18.35BENTERPRISE_VALUE
- 0.57%DIVIDEND_YIELD
- -TRADING_ACTIVITY
Track Trip.com Group Ltd (TCOM) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Trip.com Group Ltd has traded between a low of $39.84 and a high of $78.96, highlighting its annual price range. Buy and sell Trip.com Group Ltd shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Most Recent News
Quest Software achieves FedRAMP High certification for identity security in AI-driven threat era
Quest Software has obtained FedRAMP High authorization for its Quest Identity Defense and Quest Identity Recovery products on Microsoft Azure Government, making it the only provider with a FedRAMP High SaaS offering for hybrid Active Directory and Mi...
TAO Synergies appoints Bitcoin author Mark Jeffrey to boost decentralized AI and subnet investing.
TAO Synergies Inc. has appointed Mark Jeffrey, an early Bitcoin author and decentralized AI expert, as an advisor to expand its investments in Bittensor subnets and decentralized AI development. The company, which holds the largest public stake in TA...
NewcelX appoints diabetes research pioneer Dr. Camillo Ricordi to boost Type 1 diabetes therapy development.
NewcelX Ltd. has appointed Dr. Camillo Ricordi, a globally recognized expert in diabetes cure research and islet transplantation, to its Scientific Advisory Board. This move follows NewcelX's successful FDA Pre-IND meeting for its lead stem-cell ther...